PERİODONTAL ENFEKSİYONUN TEŞHİS VE PROGNOZUNDA UMUT VADEDEN BİYOBELİRTEÇLER

Yıl 2020, Cilt: 30 Sayı: 3, 499 - 506, 15.07.2020

Özlem Şahin Ata Yerda Özkan Cenk Fatih Çanakçı

https://doi.org/10.17567/ataunidfd.566916

Öz

Öz

Periodontal hastalıklar çeşitli
mikroorganizmalar tarafından başlatılmış olsa da, kompleks mikroflorası ve
konak yanıtı periodontal durumu etkilemekte ve sipesifik hastalık
belirteçlerini tanımlamayı zorlaştırmaktadır. Periodontal hastalık tanısında
kullanılan sondalamada kanama, cep derinliği, klinik ataçman seviyesi ve
radyolojik kemik miktarı gibi klinik periodontal parametreler, hastalığın
şiddetinin, prognozunun ve tedaviye verilen yanıtın değerlendirilmesinde
yetersiz kalmaktadır. Bu nedenle, dişeti oluğu sıvısı, tükürük ve serum
öneklerinde tespit edilebilen çeşitli biyobelirteçler bu konuda bize umut ışığı
olmaktadır. Son dönemlerde, doku savunma hücreleri olan adipositlerden salınan ve
adipokinler olarak adlandırılan bazı proteinler rapor edilmiştir. Bu derlemede,
çeşitli periodontal hastalıklarda çalışılmış adipokinler incelenmiş ve
gelecekte adipokinlerin bir biyobelirteç olarak periodontoloji alanında
uygulanabilirliği tartışılmıştır.

Anahtar Kelimeler: Adipokin, Yağ doku, Periodontal
hastalık, biyobelirteç

 PROMISING
BIOMARKERS IN THE DIAGNOSIS AND PROGNOSIS OF PERIODONTAL INFECTION

Abstract

Although periodontal disease is
started by various bacteria, complex microflora and the host response  affects periodontal condition and makes it
difficult to identify specific disease marker. Clinical parameters including
such as bleeding on probing, probing depth, clinical attachment level and
radiographic bone amount which used in the diagnosis of periodontal disease,
are insufficient to evaluate the severity and prognosis of disease and response
to treatment. Therefore,
various biomarkers that can be detected in gingival fluid, saliva and serum
sampels are the light of hope for us. Recently, some proteins, called
adipokines, which have been released from adipocytes as tissue defense cells,
have been reported. In this review, adipokines studied in various periodontal
diseases are investigated and the applicability of adipokines as a biomarker in
the field of periodontology is discussed.

Key Words: Adipokines,
adipose tissue, periodontal disease, biomarkers

Anahtar Kelimeler

Adipokin, Yağ doku, Periodontal hastalık

Kaynakça

• 1. Petersen PE, Ogawa H. The global burden of periodontal disease: towards integration with chronic disease prevention and control. Periodontol 2000 2012;60:15-39.
• 2. Armitage GC. Periodontal diagnoses and classification of periodontal diseases. Periodontol 2000 2004;34:9-21.
• 3. Taba M, Jr., Kinney J, Kim AS, Giannobile WV. Diagnostic biomarkers for oral and periodontal diseases. Dent Clin North Am 2005;49:551-571, vi.
• 4. ÖZER DÖ, DEMİRALP B. PERİODONTİTİS KARDİYOVASKÜLER HASTALIĞA NEDEN OLUR MU? Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi 2005;2005:62-70.
• 5. Ozcan E, Saygun NI, Serdar MA, Kurt N. Evaluation of the salivary levels of visfatin, chemerin, and progranulin in periodontal inflammation. Clin Oral Investig 2015;19:921-928.
• 6. Kukla M, Mazur W, Buldak RJ, Zwirska-Korczala K. Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis. Mol Med 2011;17:1397-1410.
• 7. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-430.
• 8. Saddi-Rosa P, Oliveira CS, Giuffrida FM, Reis AF. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr 2010;2:21.
• 9. Zhang LQ, Heruth DP, Ye SQ. Nicotinamide Phosphoribosyltransferase in Human Diseases. J Bioanal Biomed 2011;3:13-25.
• 10. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-1758.
• 11. Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 2007;56:565-570.
• 12. Pradeep AR, Raghavendra NM, Prasad MV, Kathariya R, Patel SP, Sharma A. Gingival crevicular fluid and serum visfatin concentration: their relationship in periodontal health and disease. J Periodontol 2011;82:1314-1319.
• 13. Tabari ZA, Azadmehr A, Nohekhan A, Naddafpour N, Ghaedi FB. Salivary visfatin concentrations in patients with chronic periodontitis. J Periodontol 2014;85:1081-1085.
• 14. Raghavendra NM, Pradeep AR, Kathariya R, Sharma A, Rao NS, Naik SB. Effect of non surgical periodontal therapy on gingival crevicular fluid and serum visfatin concentration in periodontal health and disease. Dis Markers 2012;32:383-388.
• 15. Mishra V, Shettar L, Bajaj M, Math AS, Thakur SL. Interlinking Periodontitis and Type 2 Diabetes Mellitus by Assessment of Crevicular Visfatin Levels in Health and in Disease Before and After Initial Periodontal Therapy. J Clin Diagn Res 2016;10:ZC67-71.
• 16. Turer CC, Balli U, Guven B, Cetinkaya BO, Keles GC. Visfatin levels in gingival crevicular fluid and serum before and after non-surgical treatment for periodontal diseases. J Oral Sci 2016;58:491-499.
• 17. Abolfazli N, Jabali S, Saleh Saber F, Babaloo Z, Shirmohammadi A. Effect of Non-surgical Periodontal Therapy on Serum and Salivary Concentrations of Visfatin in Patients with Chronic Periodontitis. J Dent Res Dent Clin Dent Prospects 2015;9:11-17.
• 18. Ghallab NA, Amr EM, Shaker OG. Expression of Leptin and Visfatin in Gingival Tissues of Chronic Periodontitis With and Without Type 2 Diabetes Mellitus: A Study Using Enzyme-Linked Immunosorbent Assay and Real-Time Polymerase Chain Reaction. J Periodontol 2015;86:882-889.
• 19. Wu Y, Chen L, Wei B, Luo K, Yan F. Effect of non-surgical periodontal treatment on visfatin concentrations in serum and gingival crevicular fluid of patients with chronic periodontitis and type 2 diabetes mellitus. J Periodontol 2015;86:795-800.
• 20. Pradeep AR, Raghavendra NM, Sharma A, et al. Association of serum and crevicular visfatin levels in periodontal health and disease with type 2 diabetes mellitus. J Periodontol 2012;83:629-634.
• 21. Filkova M, Haluzik M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol 2009;133:157-170.
• 22. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003;309:286-290.
• 23. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-783.
• 24. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005;334:1092-1101.
• 25. Patel L, Buckels AC, Kinghorn IJ, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003;300:472-476.
• 26. Mikuls TR, Payne JB, Reinhardt RA, et al. Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis. Int Immunopharmacol 2009;9:38-42.
• 27. Mittal M, Hassan B, Desai K, Duseja S, Kumar S, Reddy SG. GCF Resistin As A Novel Marker in Patients with Chronic Periodontitis and Rheumatoid Arthritis. J Clin Diagn Res 2015;9:ZC62-64.
• 28. Furugen R, Hayashida H, Yamaguchi N, et al. The relationship between periodontal condition and serum levels of resistin and adiponectin in elderly Japanese. J Periodontal Res 2008;43:556-562.
• 29. Saito T, Yamaguchi N, Shimazaki Y, et al. Serum levels of resistin and adiponectin in women with periodontitis: the Hisayama study. J Dent Res 2008;87:319-322.
• 30. Migita K, Maeda Y, Miyashita T, et al. The serum levels of resistin in rheumatoid arthritis patients. Clin Exp Rheumatol 2006;24:698-701.
• 31. Gokhale NH, Acharya AB, Patil VS, Trivedi DJ, Setty S, Thakur SL. Resistin levels in gingival crevicular fluid of patients with chronic periodontitis and type 2 diabetes mellitus. J Periodontol 2014;85:610-617.
• 32. Devanoorkar A, Dwarakanath CD, Gundanavar G, Kathariya R, Patil SR. Evaluation of serum resistin levels in periodontal health and disease and effects of non surgical periodontal therapy on its levels. Dis Markers 2012;32:289-294.
• 33. Patel SP, Raju PA. Resistin in serum and gingival crevicular fluid as a marker of periodontal inflammation and its correlation with single-nucleotide polymorphism in human resistin gene at -420. Contemp Clin Dent 2013;4:192-197.
• 34. Jain H, Mulay S. Relationship between periodontitis and systemic diseases: leptin, a new biomarker? Indian J Dent Res 2014;25:657-661.
• 35. Zhu J, Guo B, Gan X, et al. Association of circulating leptin and adiponectin with periodontitis: a systematic review and meta-analysis. BMC Oral Health 2017;17:104.
• 36. Guzik TJ, Mangalat D, Korbut R. Adipocytokines - novel link between inflammation and vascular function? J Physiol Pharmacol 2006;57:505-528.
• 37. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000;62:413-437.
• 38. Johnson RB, Serio FG. Leptin within healthy and diseased human gingiva. J Periodontol 2001;72:1254-1257.
• 39. Karthikeyan BV, Pradeep AR. Leptin levels in gingival crevicular fluid in periodontal health and disease. J Periodontal Res 2007;42:300-304.
• 40. Karthikeyan BV, Pradeep AR. Gingival crevicular fluid and serum leptin: their relationship to periodontal health and disease. J Clin Periodontol 2007;34:467-472.
• 41. Shimada Y, Komatsu Y, Ikezawa-Suzuki I, Tai H, Sugita N, Yoshie H. The effect of periodontal treatment on serum leptin, interleukin-6, and C-reactive protein. J Periodontol 2010;81:1118-1123.
• 42. Altay U, Gurgan CA, Agbaht K. Changes in inflammatory and metabolic parameters after periodontal treatment in patients with and without obesity. J Periodontol 2013;84:13-23.
• 43. Kardesler L, Buduneli N, Cetinkalp S, Kinane DF. Adipokines and inflammatory mediators after initial periodontal treatment in patients with type 2 diabetes and chronic periodontitis. J Periodontol 2010;81:24-33.
• 44. Bozkurt FY, Yetkin Ay Z, Sutcu R, Delibas N, Demirel R. Gingival crevicular fluid leptin levels in periodontitis patients with long-term and heavy smoking. J Periodontol 2006;77:634-640.
• 45. de Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007;56:1655-1661.
• 46. Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010;88:29-33.
• 47. Senolt L, Polanska M, Filkova M, et al. Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. Ann Rheum Dis 2010;69:1410-1411.
• 48. Zhong X, Zhang HY, Tan H, et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin 2011;32:873-878.
• 49. Tan BK, Adya R, Farhatullah S, Chen J, Lehnert H, Randeva HS. Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes 2010;59:3023-3031.
• 50. Zhong X, Li X, Liu F, Tan H, Shang D. Omentin inhibits TNF-alpha-induced expression of adhesion molecules in endothelial cells via ERK/NF-kappaB pathway. Biochem Biophys Res Commun 2012;425:401-406.
• 51. Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun 2010;393:668-672.
• 52. Tan BK, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 2010;20:143-148.
• 53. Bozkurt Dogan S, Ongoz Dede F, Balli U, Sertoglu E. Levels of vaspin and omentin-1 in gingival crevicular fluid as potential markers of inflammation in patients with chronic periodontitis and type 2 diabetes mellitus. J Oral Sci 2016;58:379-389.
• 54. Jian W, Peng W, Xiao S, et al. Role of serum vaspin in progression of type 2 diabetes: a 2-year cohort study. PLoS One 2014;9:e94763.
• 55. Youn BS, Kloting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008;57:372-377.
• 56. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005;102:10610-10615.
• 57. Wang YM, Wang WP, Wang LP, Lu QH, Zhou XH. Calorie control increased vaspin levels of serum and periepididymal adipose tissue in diet-induced obese rats in association with serum free fatty acid and tumor necrosis factor alpha. Chin Med J (Engl) 2010;123:936-941.
• 58. Pradeep AR, Karvekar S, Nagpal K, Patnaik K. Vaspin: a new adipokine correlating the levels of crevicular fluid and tear fluid in periodontitis and obesity. J Investig Clin Dent 2016;7:232-238.
• 59. Balli U, Bozkurt Dogan S, Ongoz Dede F, Sertoglu E, Keles GC. The levels of visceral adipose tissue-derived serpin, omentin-1 and tumor necrosis factor-alpha in the gingival crevicular fluid of obese patients following periodontal therapy. J Oral Sci 2016;58:465-473.
• 60. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-660.
• 61. Tanaka M, Hayashida Y, Iguchi T, Nakao N, Nakai N, Nakashima K. Organization of the mouse ghrelin gene and promoter: occurrence of a short noncoding first exon. Endocrinology 2001;142:3697-3700.
• 62. Nagaya N, Kangawa K. Ghrelin, a novel growth hormone-releasing peptide, in the treatment of chronic heart failure. Regul Pept 2003;114:71-77.
• 63. Cassoni P, Papotti M, Ghe C, et al. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab 2001;86:1738-1745.
• 64. Dornonville de la Cour C, Lindstrom E, Norlen P, Hakanson R. Ghrelin stimulates gastric emptying but is without effect on acid secretion and gastric endocrine cells. Regul Pept 2004;120:23-32.
• 65. Hataya Y, Akamizu T, Takaya K, et al. A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J Clin Endocrinol Metab 2001;86:4552.
• 66. Nokhbehsaim M, Damanaki A, Nogueira AVB, et al. Regulation of Ghrelin Receptor by Periodontal Bacteria In Vitro and In Vivo. Mediators Inflamm 2017;2017:4916971.
• 67. Jentsch HFR, Arnold N, Richter V, Deschner J, Kantyka T, Eick S. Salivary, gingival crevicular fluid and serum levels of ghrelin and chemerin in patients with periodontitis and overweight. J Periodontal Res 2017;52:1050-1057.
• 68. Yilmaz G, Kirzioglu FY, Doguc DK, Kocak H, Orhan H. Ghrelin levels in chronic periodontitis patients. Odontology 2014;102:59-67.
• 69. Aronis KN, Sahin-Efe A, Chamberland JP, Spiro A, 3rd, Vokonas P, Mantzoros CS. Chemerin levels as predictor of acute coronary events: a case-control study nested within the veterans affairs normative aging study. Metabolism 2014;63:760-766.
• 70. Goralski KB, McCarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007;282:28175-28188.
• 71. Zabel BA, Zuniga L, Ohyama T, et al. Chemoattractants, extracellular proteases, and the integrated host defense response. Exp Hematol 2006;34:1021-1032.
• 72. Albadah MS, Dekhil H, Shaik SA, et al. Effect of weight loss on serum osteocalcin and its association with serum adipokines. Int J Endocrinol 2015;2015:508532.
• 73. Yoshimura T, Oppenheim JJ. Chemokine-like receptor 1 (CMKLR1) and chemokine (C-C motif) receptor-like 2 (CCRL2); two multifunctional receptors with unusual properties. Exp Cell Res 2011;317:674-684.
• 74. Cash JL, Norling LV, Perretti M. Resolution of inflammation: targeting GPCRs that interact with lipids and peptides. Drug Discov Today 2014;19:1186-1192.
• 75. Bondue B, Wittamer V, Parmentier M. Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev 2011;22:331-338.
• 76. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007;148:4687-4694.
• 77. Fatima SS, Rehman R, Baig M, Khan TA. New roles of the multidimensional adipokine: chemerin. Peptides 2014;62:15-20.
• 78. Balli U, Ongoz Dede F, Bozkurt Dogan S, Gulsoy Z, Sertoglu E. Chemerin and interleukin-6 levels in obese individuals following periodontal treatment. Oral Dis 2016;22:673-680.
• 79. Dogan SB, Balli U, Dede FO, Sertoglu E, Tazegul K. Chemerin as a Novel Crevicular Fluid Marker of Patients With Periodontitis and Type 2 Diabetes Mellitus. J Periodontol 2016;87:923-933.